Catalyst Biosciences raises $40 Million in series C financing
Printer Print Email Email
San Francisco: Catalyst Biosciences, a pioneer in the discovery and development of engineered proteases known as Alterase therapeutics, has raised $40.4 million in a series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. Nassim Usman, Chief Executive Officer of Catalyst Biosciences, said, "The financing provides us with several years of funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase 1/2 proof-of-concept studies in patients." In conjunction with the financing, Jeff Himawan from Essex Woodlands will join Catalyst Biosciences' Board of Directors. "Catalyst's protease therapeutics platform has the potential to deliver a new class of biologics addressing numerous diseases. The company has made excellent progress in the establishment of their discovery capabilities and the progress of their pipeline," said Dr. Himawan on behalf of the Board.